Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Income-Before-Tax" stands at 16.42 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2022.
Novartis AG's third quarter result of 4.20 Billion USD for the item "Income Before Tax" represents a decrease of -7.39 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 4.20 Billion USD for the item "Income Before Tax" represents an increase of 23.96 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 16.42 Billion USD for the item "Income Before Tax" represents an increase of 5.20 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 28.96 percent compared to the value the year prior.
The 1 year change in percent is 28.96.
The 3 year change in percent is -29.38.
The 5 year change in percent is 80.87.
The 10 year change in percent is 68.24.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Income Before Tax | 905,699,262,464.00 |
![]() | Johnson & Johnson - Income Before Tax | 486,508,953,600.00 |
![]() | AbbVie Inc - Income Before Tax | 399,570,305,024.00 |
![]() | Roche Holding AG - Income Before Tax | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Income Before Tax | 280,205,508,085.11 |